What is Global Recombinant Plasma Protein Therapeutics Market?
The Global Recombinant Plasma Protein Therapeutics Market is a rapidly evolving sector that focuses on the development and distribution of therapeutic proteins derived from recombinant DNA technology. These proteins are designed to replace or augment the function of plasma proteins that are deficient or dysfunctional in certain diseases. The market encompasses a wide range of products, from clotting factors for hemophilia to enzymes for lysosomal storage disorders. The global market is driven by the increasing prevalence of diseases requiring plasma-derived therapies, advancements in recombinant DNA technology, and the growing demand for safer and more effective therapeutic options. The market is also influenced by regulatory policies, pricing and reimbursement issues, and the competitive landscape of pharmaceutical and biotechnology companies.
Recombinant Coagulation Factors, Human C1 Esterase Inhibitor in the Global Recombinant Plasma Protein Therapeutics Market:
Recombinant Coagulation Factors and Human C1 Esterase Inhibitor are two key segments of the Global Recombinant Plasma Protein Therapeutics Market. Recombinant Coagulation Factors are bioengineered versions of the proteins that help blood to clot. They are primarily used in the treatment of hemophilia, a genetic disorder characterized by the inability of blood to clot normally. Human C1 Esterase Inhibitor is a plasma protein that regulates several inflammatory pathways in the body. It is used in the treatment of hereditary angioedema, a rare and potentially life-threatening condition characterized by episodes of severe swelling. The development and commercialization of these recombinant plasma proteins have revolutionized the treatment of these diseases, offering patients safer, more effective, and more convenient therapeutic options.
Hemophilia A, Hemophilia B, Von Willebrand Disease in the Global Recombinant Plasma Protein Therapeutics Market:
The Global Recombinant Plasma Protein Therapeutics Market plays a crucial role in the treatment of several bleeding disorders, including Hemophilia A, Hemophilia B, and Von Willebrand Disease. Hemophilia A and B are genetic disorders caused by the deficiency of clotting factors VIII and IX, respectively. They are characterized by spontaneous bleeding episodes and prolonged bleeding after injury or surgery. Von Willebrand Disease is another genetic bleeding disorder caused by the deficiency or dysfunction of von Willebrand factor, a protein that helps blood to clot. Recombinant plasma protein therapeutics, such as recombinant factor VIII, IX, and von Willebrand factor, have significantly improved the management of these diseases, reducing the risk of bleeding complications and improving the quality of life for patients.
Global Recombinant Plasma Protein Therapeutics Market Outlook:
The future of the Global Recombinant Plasma Protein Therapeutics Market looks promising, with a steady growth trajectory projected over the next few years. In 2023, the market was valued at US$ 92 million and is expected to reach US$ 136.1 million by 2030, growing at a compound annual growth rate (CAGR) of 5.8%. This growth is in line with the overall expansion of the global medical devices market, which was estimated at US$ 603 billion in 2023 and is projected to grow at a CAGR of 5% over the next six years. The growth of the Recombinant Plasma Protein Therapeutics Market is driven by the increasing prevalence of diseases requiring plasma-derived therapies, advancements in recombinant DNA technology, and the growing demand for safer and more effective therapeutic options.
| Report Metric | Details |
| Report Name | Recombinant Plasma Protein Therapeutics Market |
| Accounted market size in 2023 | US$ 92 million |
| Forecasted market size in 2030 | US$ 136.1 million |
| CAGR | 5.8% |
| Base Year | 2023 |
| Forecasted years | 2024 - 2030 |
| Segment by Type |
|
| Segment by Application |
|
| Consumption by Region |
|
| By Company | CSL Limited, Takeda, Octapharma, Novo Nordisk A/S, Pfizer, Bioverativ Therapeutics, Aptevo Therapeutics, Pharming Group |
| Forecast units | USD million in value |
| Report coverage | Revenue and volume forecast, company share, competitive landscape, growth factors and trends |
